MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Country |
 USA |
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
75 M |
Market Cap[1] |
$ 6.74 B |
EBITDA (LTM) |
$ -316 M |
P/E (LTM) |
-25.3 |
P/S (LTM) |
167.23 |
EPS (LTM) |
-3.53 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 25.27 | -2.43 % | $ 1.22 B | Nasdaq Global Select Market | USA |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.75 | 1.61 % | $ 788 M | Nasdaq Global Select Market |  Canada |
 |
Aclaris Therapeutics
ACRS
|
$ 3.26 | -3.12 % | $ 252 M | Nasdaq Global Select Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Kamada Ltd.
KMDA
|
$ 7.03 | 0.14 % | $ 260 M | Nasdaq Global Select Market |  Israel |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 220.27 | 4.81 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.91 | -5.01 % | $ 18.7 M | Nasdaq Capital Market | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 0.28 | -2.28 % | $ 609 M | NYSE American | Israel |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.3 | -3.51 % | $ 7.94 B | Nasdaq Capital Market |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
AstraZeneca PLC
AZN
|
$ 89.78 | -0.57 % | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Anika Therapeutics
ANIK
|
$ 9.57 | 0.84 % | $ 140 M | Nasdaq Global Select Market,SPB | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
 |
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | USA |
 |
Benitec Biopharma
BNTC
|
$ 12.05 | -7.06 % | $ 496 M | Nasdaq Capital Market | USA |
 |
Aytu BioScience
AYTU
|
$ 2.34 | 2.59 % | $ 14.7 M | Nasdaq Capital Market | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
- | -19.68 % | $ 18.4 M | Nasdaq Capital Market | Canada |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Aptorum Group Limited
APM
|
$ 1.29 | -3.01 % | $ 7.03 M | Nasdaq Global Select Market |  China |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Baudax Bio
BXRX
|
- | 0.59 % | $ 63 K | Nasdaq Capital Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Catalyst Biosciences
CBIO
|
$ 14.01 | -8.49 % | $ 922 M | Nasdaq Capital Market | USA |
 |
ChromaDex Corporation
CDXC
|
- | -0.88 % | $ 598 M | Nasdaq Capital Market | USA |
 |
Axon Enterprise
AXON
|
$ 566.18 | -2.56 % | $ 42.9 B | Nasdaq Global Select Market,SPB | USA |
 |
Cerus Corporation
CERS
|
$ 2.16 | 0.47 % | $ 399 M | Nasdaq Global Market | USA |
 |
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | USA |
 |
Caladrius Biosciences
CLBS
|
- | -16.75 % | $ 25.8 M | Nasdaq Capital Market | USA |
 |
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | USA |
 |
Biogen
BIIB
|
$ 174.42 | 1.11 % | $ 25.4 B | Nasdaq Global Select Market,SPB | USA |
 |
BioVie
BIVI
|
$ 1.42 | -5.96 % | $ 2.1 M | Nasdaq Capital Market | USA |
 |
Celldex Therapeutics
CLDX
|
$ 27.36 | -2.09 % | $ 1.76 M | Nasdaq Global Select Market | USA |
 |
Cortexyme
CRTX
|
- | -1.05 % | $ 67.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Cellectar Biosciences
CLRB
|
$ 3.63 | -3.97 % | $ 44.4 M | Nasdaq Capital Market | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.54 | 0.87 % | $ 746 M | NYSE | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.